Skip to main content
Market snapshot: . Prices may have changed since this snapshot.
Events
GroupKALSHI
Will the FDA approve MDMA for PTSD?
Will the FDA approve MDMA for PTSD?
Reported volume
K 13.7K contracts
Events
1
Markets
6

Current odds

Snapshot from

As of Nov 22, 2026, 12:00 PM UTC, the highest-priced outcome on Kalshi is Before Jan 1, 2031 at 54%.

Kalshi

  1. Before Jan 1, 203154%
  2. Before Jan 1, 203053%
  3. Before Jan 1, 202952%
  4. Before Jan 1, 203251.5%
  5. Before Jan 1, 202842.5%

Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.

AI Analysis

Trader mode: Market mechanics, assumptions and risks

K 13.7K contracts

Reported volume · provider units

6

Saved contracts

0

Same-question pairs

Source snapshot: Nov 22, 2026, 12:00 PM UTC

This analysis was written from an earlier market snapshot, so its prices may be older than the odds above.

Snapshot observed Nov 19, 2026, 3:00 AM UTC. This analysis describes that snapshot and is not a live news update.

What the contract measures

The Kalshi event asks whether the FDA will approve midomafetamine / MDMA for PTSD before a stated deadline [1]. Qualifying approvals include standard approval, traditional approval based on clinical benefit, accelerated approval based on surrogate endpoints, and approval with a REMS or restricted indication. Complete Response Letters, approvable letters, Emergency Use Authorization, and compassionate use programs do not count [1]. If the sponsor withdraws the application before FDA action, the market resolves to No. An accelerated approval that is later withdrawn still resolves Yes if the initial approval occurred [1].

The six markets share this rule text but differ in deadline. Their titles name January 1 of each year from 2027 through 2032 [1]. The excerpt uses the placeholder "X" where a date would appear, so the year in each title is the only deadline wording supplied.

Reading the snapshot

The prices below were observed at Nov 19, 2026, 3:00 AM UTC and retrieved at 03:38:20Z [1]. They describe that moment only.

  • Before Jan 1, 2027: Yes 0.09, No 0.91
  • Before Jan 1, 2028: Yes 0.425, No 0.575
  • Before Jan 1, 2029: Yes 0.52, No 0.48
  • Before Jan 1, 2030: Yes 0.53, No 0.47
  • Before Jan 1, 2031: Yes 0.54, No 0.46
  • Before Jan 1, 2032: Yes 0.515, No 0.485

These are snapshot prices, not executable quotes or verified probabilities. Yes prices generally rise from 2027 to 2031, then dip slightly for 2032. The sample includes all six Kalshi markets for this event, with partialSample set to false [1]. The reported volume of 13,740 contracts uses Kalshi's own unit for this event. It should not be compared with other platforms or read as liquidity.

The provider's market end timestamps, such as Jan 8, 2027, 3:00 PM UTC, do not match the January 1 titles. The excerpt also states that the listed end time is not supplied [1]. Neither figure should be treated as confirmed closing or resolution timing.

What remains uncertain

Only Kalshi data is supplied, so no cross-platform comparison is possible. The sample warning notes that all saved markets are included, but this does not establish that the provider lists every possible real-world outcome [1]. The evidence does not explain why prices differ across deadlines or what caused any movement. It also contains no news about the application, the sponsor's status, or any scheduled FDA action. Whether the market resolves as written depends on events not covered by this snapshot.

References

  1. Kalshi: Will the FDA approve MDMA for PTSD?. Provider data observed Nov 19, 2026, 3:00 AM UTC.

AI-generated analysis based on market data. Not financial advice.

Saved Nov 19, 2026 UTC

This article was written from an earlier market snapshot and may be out of date. Use the dated market data and provider rules above for current information.

Overview

This contract asks whether the U.S. Food and Drug Administration (FDA) will approve midomafetamine / MDMA for post-traumatic stress disorder (PTSD) before a stated date. The contract rules use the name "midomafetamine / MDMA" [1]. MDMA itself is described in the background sources as "an entactogen with stimulant and minor psychedelic properties" [2]. A separate Wikipedia entry describes MDMA/citalopram, a combination of MDMA and the SSRI citalopram, as "under development for the treatment of post-traumatic stress disorder (PTSD)" [3]. That entry concerns the combination product, so it should not be read as describing the product named in the contract. The Kalshi contract resolves to Yes if the FDA approves the drug for marketing before the relevant January 1 deadline. The rules define an approval by type of application. For new drugs, it is the issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA). For already-marketed drugs seeking a new indication, it is approval of a supplemental application for that indication [1]. Standard approvals, accelerated approvals, approvals with a Risk Evaluation and Mitigation Strategy (REMS), and approvals with restricted distribution or indication limits all count [1]. Several outcomes do not count as approval under the rules. These include Complete Response Letters (CRLs), approvable letters that require further action, tentative approvals, requests for more information or studies, extensions of user fee dates, Emergency Use Authorizations without full approval, and approvals limited to compassionate use or export [1]. The rules also address specific scenarios. A CRL before the deadline resolves the market to No unless the FDA later approves the drug after addressing the CRL concerns and before the second deadline [1]. An approval granted after an Advisory Committee vote against approval still resolves Yes [1]. An accelerated approval that is later withdrawn still resolves Yes, because the question concerns whether the initial approval occurred [1]. If the sponsor withdraws the application before FDA action, the market resolves to No immediately, and the market closes early if the event occurs [1].

Historical Context

The supplied sources do not describe the regulatory review history of MDMA or of midomafetamine / MDMA for PTSD. They do establish that MDMA is known as ecstasy in tablet form and molly in crystal form [2], and that the MDMA/citalopram combination is described as under development for PTSD [3].

Why It Matters

The contract measures whether a specific regulatory action occurs by a stated date. It does not measure whether the drug is clinically effective, and the supplied sources do not evaluate its safety or efficacy. The prices show how the market has priced that regulatory outcome at the time of the snapshot. Each price is a snapshot, not an executable quote or a verified probability [1]. The Kalshi event contains six date-specific contracts, ranging from a Yes price of 0.09 for a deadline in 2027 to 0.54 for a deadline in 2031 [1]. The reported volume of 13,740 contracts is the total Kalshi reports for its own event. It is not a measure of liquidity or the number of traders [1]. The contract end timestamps in the saved market data are dated January 8, while the rule text refers to January 1. The supplied material does not explain this difference, so the rule text should be checked directly before relying on a deadline.

Snapshot context

The latest published provider snapshot for this topic was observed on 2026-11-19 at 03:00 UTC. It contains listings from Kalshi. Market descriptions and listed closing times define the contracts; they do not establish that the real-world outcome has occurred. This article does not include a separately verified news update. [1]

Frequently Asked Questions

Would a Complete Response Letter count as approval?

No. The rules state that Complete Response Letters indicate the application cannot be approved in its current form and do not constitute an approval [1].

Does an Emergency Use Authorization resolve the market to Yes?

The rules say an Emergency Use Authorization without full approval does not constitute an approval [1].

What happens if the sponsor withdraws the application before FDA action?

The rules say the market resolves to No immediately if the drug sponsor withdraws the application before FDA action and before the deadline, and the market closes early [1].

Was this helpful?
Saved Nov 19, 2026 UTC

AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.

Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

KalshiHealth
Will the FDA approve VERVE-102?

Will the FDA approve VERVE-102?

K 1.8K contracts
Will the FDA approve VERVE-102 before Jan 1, 2035?Yes 83.5%
Will the FDA approve VERVE-102 before Jan 1, 2034?Yes 77.5%
Will the FDA approve VERVE-102 before Jan 1, 2033?Yes 75.5%
+3 moreNext deadline Jan 1, 2030 UTC
PolymarketKalshiScience
Will the FDA approve retatrutide?

Will the FDA approve retatrutide?

PM $599.3K · K 121.2K contracts

FDA approves Retatrutide this year?

Kalshi: When will the FDA approve retatrutide (LY3437943)? (Before Jan 1, 2027)

Same question, fine print differs

PM Yes 1.3%Rules differK Yes 1.5%

Related or unreviewed contracts may settle differently. Their gap is not an equivalent-contract comparison.

Saved prices; check contract rules.

1 saved comparisonNext deadline Jan 1, 2027 UTC
KalshiHealth
When will the FDA approve Compass Pathways' COMP360 Psilocybin?

When will the FDA approve Compass Pathways' COMP360 Psilocybin?

K 28.1K contracts
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before 2028)Yes 90.5%
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before October 2027)Yes 88%
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before July 2027)Yes 83.5%
+2 moreNext deadline Jan 1, 2027 UTC
KalshiHealth
Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

K 3.2K contracts
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?Yes 95%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?Yes 85.5%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?Yes 64.5%
+2 moreNext deadline Apr 1, 2027 UTC
KalshiHealth
Will the FDA approve CagriSema?

Will the FDA approve CagriSema?

K 7.1K contracts
Will the FDA approve CagriSema before Jan 1, 2027?Yes 96.5%
Will the FDA approve CagriSema before Jan 1, 2028?Yes 93%
Will the FDA approve CagriSema before Jul 1, 2027?Yes 92%
3 mktsNext deadline Jan 1, 2027 UTC
KalshiHealth
When will the FDA approve Intellia Therapeutics' lonvo-z?

When will the FDA approve Intellia Therapeutics' lonvo-z?

K 6.6K contracts
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)Yes 92.5%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)Yes 92%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)Yes 89%
3 mktsNext deadline Jul 1, 2027 UTC

Market Insights

Price gaps of 2 pp+

0

Same-question pairs

0

No outcomes on this page have been reviewed as the same question on both platforms yet.

Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.

Trade This Market